Comparing blood thinners in antiphospholipid syndrome
Part of Immune system & allergy clinical trials.
This study compares two types of blood thinners (DOACs like rivaroxaban or apixaban, and vitamin K blockers like warfarin) in people with antiphospholipid syndrome who had a vein clot. The goal is to see which one works better at preventing future clots without causing more bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have had a blood clot in a vein (not an artery).
- You have been diagnosed with antiphospholipid syndrome (APS) based on blood tests that stayed positive for at least 12 weeks.
- You are currently taking a blood thinner: either a DOAC (like rivaroxaban or apixaban) or warfarin (a vitamin K blocker).
- Your clot was not caused by a major trigger like active cancer, major surgery, or a long hospital stay.
- You do not have 'triple positive' APS, nor have you had artery or microscopic blood clots.
- You have not had a new clot while on your current blood thinner.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well blood thinners prevent blood clots from coming back in people with antiphospholipid syndrome (APS) who are considered low risk. It compares two types of medicines: direct oral anticoagulants (DOACs) and vitamin K antagonists.
This study observes patients with antiphospholipid syndrome who are taking or have taken direct oral anticoagulants (blood thinners) to better understand their treatment experiences and outcomes.
This study compares two types of blood thinners (vitamin K antagonists) in people with antiphospholipid syndrome, a condition where the immune system attacks healthy cells and increases blood clot risk. The goal is to see if one is better at preventing future blood clots.
This study keeps an international registry of people with antiphospholipid syndrome (APS) who are taking direct oral blood thinners. It may help doctors better understand how APS patients do over time and improve future care, even if you’re not asked to change treatment.
This study keeps a registry to follow people with antiphospholipid syndrome (APS) who have had arterial blood clots (like stroke). It collects information about the treatment approach your clinician chooses to see how different antithrombotic regimens may perform and be tolerated.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.